ZA708468B - Optical isomers of ketamine and process for the resolution thereof - Google Patents

Optical isomers of ketamine and process for the resolution thereof

Info

Publication number
ZA708468B
ZA708468B ZA708468A ZA708468A ZA708468B ZA 708468 B ZA708468 B ZA 708468B ZA 708468 A ZA708468 A ZA 708468A ZA 708468 A ZA708468 A ZA 708468A ZA 708468 B ZA708468 B ZA 708468B
Authority
ZA
South Africa
Prior art keywords
ketamine
resolution
optical isomers
isomers
optical
Prior art date
Application number
ZA708468A
Inventor
I Hooper
T Hudyma
S Holmes
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of ZA708468B publication Critical patent/ZA708468B/en

Links

ZA708468A 1969-12-19 1970-12-15 Optical isomers of ketamine and process for the resolution thereof ZA708468B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88679969A 1969-12-19 1969-12-19

Publications (1)

Publication Number Publication Date
ZA708468B true ZA708468B (en) 1972-02-23

Family

ID=25389797

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA708468A ZA708468B (en) 1969-12-19 1970-12-15 Optical isomers of ketamine and process for the resolution thereof

Country Status (9)

Country Link
JP (1) JPS4948542B1 (en)
BE (1) BE760492A (en)
CH (1) CH535201A (en)
DE (1) DE2062620A1 (en)
ES (1) ES386601A1 (en)
FR (1) FR2081388B1 (en)
GB (1) GB1330878A (en)
NL (1) NL7018334A (en)
ZA (1) ZA708468B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5875614A (en) * 1981-10-28 1983-05-07 Matsushita Electric Ind Co Ltd Exhaust gas purifying device for incinerator
DE4312016A1 (en) * 1993-04-13 1994-10-20 Goedecke Ag Stable ketamine solutions
DE19619665C2 (en) * 1996-05-15 2001-03-08 Goedecke Ag Racemate separation of ketamine
BRPI0002693B8 (en) * 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda process for obtaining the enantiomers of ketamine and its pharmaceutically acceptable salts
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EA017264B1 (en) 2005-09-28 2012-11-30 Аурис Медикаль Аг Use of arylcycloalkylamide composition for preparing a medicament for the treatment of inner ear disorder
US20150044200A1 (en) 2011-12-12 2015-02-12 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
SG11201507347QA (en) 2013-03-15 2015-10-29 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP3964203A1 (en) 2013-09-13 2022-03-09 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3725307A1 (en) 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (en) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression.
CN111936127A (en) 2018-02-15 2020-11-13 国立大学法人千叶大学 Agent for preventing or treating inflammatory disease or bone disease, and pharmaceutical composition
CN110218157B (en) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 Preparation method of R-ketamine and its medicinal salt
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2020003195A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
KR20210074275A (en) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 Dosage regimen of esketamine to treat major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
MX2021010683A (en) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression.
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
CN112125816A (en) * 2020-03-17 2020-12-25 国药集团工业有限公司 Racemization method of ketamine, its derivative or its salt

Also Published As

Publication number Publication date
JPS4948542B1 (en) 1974-12-21
BE760492A (en) 1971-06-17
NL7018334A (en) 1971-06-22
DE2062620A1 (en) 1971-07-15
CH535201A (en) 1973-03-31
GB1330878A (en) 1973-09-19
FR2081388B1 (en) 1974-06-21
ES386601A1 (en) 1974-01-16
FR2081388A1 (en) 1971-12-03

Similar Documents

Publication Publication Date Title
ZA708468B (en) Optical isomers of ketamine and process for the resolution thereof
CA953720A (en) PROCESS FOR THE PRODUCTION OF 2-BROMO-.alpha.-ERGOCRYPTINE
ZA713298B (en) Resolution process
YU36877A (en) Process for the synthesis of thioureidobenzene
PH9229A (en) Process for the preparation of 3-phenyl-5-t-butyl-2-oxadiazolones
IL33920A0 (en) Process for the manufacture of oximino-dithiolanes
IL32953A0 (en) Process for the preparation of delta3-thiazolines
YU35057B (en) Apparatus for the manufacture of dichloroethane
GB1324540A (en) Process for the productions of cis-polypentenamers
IL33829A0 (en) Process for the preparation of alpha-cyanobutyraldimines
ZA703957B (en) Process for the preparation of quinoxaline-di-n-oxide-aldehyde
ZA717827B (en) Coating process
AU447614B2 (en) Optical isomers of ketamine and process forthe resolution thereof
ZA70543B (en) Coating process
AU2353170A (en) Optical isomers of ketamine and process forthe resolution thereof
IL35163A (en) Process for the preparation of 3-halomethyl-cephalosporins and some such compounds
IL34184A (en) Process for the preparation of 19-nor-steroids
ZA706014B (en) Coating process
AU426654B2 (en) Resolution process
IL35069A (en) Process for the preparation of 3-phenyl-5-t-butyl-2-oxadiazolones
IL35502A0 (en) Process for the manufacture of n-mercaptomethyl-phthalimide
AU4933469A (en) Resolution process
CA808170A (en) Polycyclic compounds and photochemical process
CA819768A (en) Process for the hydrogenation of nitriles
CA786377A (en) Process for the preparation of alpha substituted alkanedinitriles